Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Nature Medicine

Volumn 23, Issue 10, 2017, Pages 1146-1149

  Mire, Chad E ^a,b   Cross, Robert W ^a,b   Geisbert, Joan B ^a,b   Borisevich, Viktoriya ^a,b   Agans, Krystle N ^a,b   Deer, Daniel J ^c   Heinrich, Megan L ^c   Rowland, Megan M ^d,e   Goba, Augustine ^d,e,f   Momoh, Mambu ^c   Boisen, Mathew L ^d,e   Grant, Donald S ^c   Fullah, Mohamed ^d,e   Khan, Sheik Humarr ^d,e   Fenton, Karla A ^a,b   Robinson, James E ^g   Branco, Luis M ^c   Garry, Robert F ^c,g,h   Geisbert, Thomas W ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Zalgen Labs   (United States)

^d Kenema Government Hospital   (Sierra Leone)

^e MINISTRY OF HEALTH AND SANITATION   (Sierra Leone)

^f Polytechnic College   (Sierra Leone)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS RNA;

AFRICA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CROSS REACTIVITY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VITRO STUDY; KAPLAN MEIER METHOD; LASSA FEVER; LASSA VIRUS; MACACA FASCICULARIS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNE EVASION; RANDOMIZATION; SURVIVAL RATE; VIRUS LOAD;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; LASSA FEVER; LASSA VIRUS; MACACA FASCICULARIS; RANDOM ALLOCATION; RNA, VIRAL; SURVIVAL RATE; VIRAL LOAD;

EID: 85030792224     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4396     Document Type: Article

References (20)

1. McCormick, J.B., Webb, P.A., Krebs, J.W., Johnson, K.M. & Smith, E.S. J. Infect. Dis. 155, 437-444 (1987).
2. Shaffer, J.G. et al. PLoS Negl. Trop. Dis. 8, e2748 (2014).
3. World Health Organization. Lassa Fever-Nigeria. Available at: http://www.who. int/csr/don/28-june-2017-lassa-fever-nigeria/en/. (Accessed 5 July 2017).
4. Schmitz, H. et al. Microbes Infect. 4, 43-50 (2002).
5. Amorosa, V. et al. Emerg. Infect. Dis. 16, 1598-1600 (2010).
6. Fisher-Hoch, S.P., Hutwagner, L., Brown, B. & McCormick, J.B. J. Virol. 74, 6777-6783 (2000).
7. Geisbert, T.W. et al. PLoS Med. 2, e183 (2005).
8. Jahrling, P.B. et al. J. Infect. Dis. 141, 580-589 (1980).
9. Jahrling, P.B., Peters, C.J. & Stephen, E.L. J. Infect. Dis. 149, 420-427 (1984).
10. Jahrling, P.B. & Peters, C.J. Infect. Immun. 44, 528-533 (1984).
11. McCormick, J.B. et al. N. Engl. J. Med. 314, 20-26 (1986).
12. Leifer, E., Gocke, D.J. & Bourne, H. Am. J. Trop. Med. Hyg. 19, 677-679 (1970).
13. Emond, R.T., Bannister, B., Lloyd, G., Southee, T.J. & Bowen, E.T. Br. Med. J. 285, 1001-1002 (1982).
14. Frame, J.D., Verbrugge, G.P., Gill, R.G. & Pinneo, L. Trans. R. Soc. Trop. Med. Hyg. 78, 319-324 (1984).
15. Cao, W. et al. Science 282, 2079-2081 (1998).
16. Robinson, J.E. et al. Nat. Commun. 7, 11544 (2016).
17. Cross, R.W. et al. Antiviral Res. 133, 218-222 (2016).
18. Thi, E.P. et al. Nature 521, 362-365 (2015).
19. Thi, E.P. et al. Sci. Transl. Med. 6, 250ra116 (2014).
20. Grove, J.N. et al. Virol. J. 8, 314-314 (2011).